Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance

United States Army Medical Research and Development Command (USAMRDC)

Status: Completed

Conditions: Biomarkers, Pharmacological

Treatments: Drug: Donepezil; Drug: Galantamine; Other: Placebo; Drug: Huperzine A

Study type: Observational

Funder types: Other U.S. Federal agency

Identifiers

NCT01194336

A-16072 (Other Identifier)

WRAIR 1650

Details and patient eligibility

About

The primary objective of this study is to determine whether huperzine A, donepezil, and galantamine impact militarily relevant aspects of neurocognitive performance in humans, compared to placebo.

Full description

The primary objective of this study is to determine whether huperzine A, donepezil, and galantamine impact militarily relevant aspects of neurocognitive performance in humans, compared to placebo.

Secondary: Secondary objectives are to correlate neurocognitive performance effects with degree of inhibition and therefore sequestration of red blood cell AChE by huperzine A, donepezil, and galantamine, and to monitor the safety of the study drugs in healthy adult (18-39 years) males and females.

In a double-blind, randomized, placebo-controlled, parallel-groups design, normal, healthy, adult male and female volunteers will be administered one of the drug/doses. They will be tested prior to and periodically for militarily relevant performance tasks for up to 8 hours post-dose and for cholinesterase levels via finger prick.

Enrollment: 84 patients

Sex: All

Ages: 18 to 39 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• All healthy men and women 18 to 39 years of age are eligible to participate.

Exclusion criteria

Must be able to swallow whole pills.

• Self-reported habitual nightly sleep amounts outside the target range of 6-8 hours (i.e., less than 6 hours per night or more than 8 hours per night, on average)
• Cardiovascular disease (to include but not limited to arrhythmias, valvular heart disease, congestive heart failure, family history of sudden cardiac death or myocardial infarction) as determined by participant self report.
• Current hypertension or high blood pressure (greater than 140/90)
• Neurologic disorder (to include but not limited to epilepsy or another seizure disorder, amnesia for any reason, hydrocephalus, MS, narcolepsy or other sleep disorders)
• Kidney disease
• History of psychiatric disorder requiring hospitalization or psychiatric medication for any length of time
• Beck Depression Inventory score of 14 or above
• Underlying pulmonary disease requiring daily inhaler use
• Regular nicotine use (or addiction) (defined as more than 1 cigarette or equivalent per week) within the last 3 years
• Heavy alcohol use (more than 2 drinks per day; http://www.cdc.gov/alcohol/faqs.htm#10)
• Use of other illicit drugs (to include but not limited to benzodiazepines, amphetamines, cocaine, marijuana)
• Known liver disease or liver abnormalities as determined by a laboratory test
• Known ulcer disease or risk of ulcer disease (stomach bleeding)
• Self-reported history of caffeine use in excess of 400 mg (8 caffeinated sodas or 3-4 cups, each ~ 6 oz, of coffee) per day on average
• Pregnancy (females)
• Breast-feeding (females)
• Prior anaphylactic reaction, angioedema, or other severe psychological reactions to any of the test compounds

Trial design

84 participants in 7 patient groups

Huperzine A: 100 ug

Treatment:

Drug: Huperzine A

Huperzine A: 200 ug

Treatment:

Drug: Huperzine A

Donepezil: 2.5 mg

Treatment:

Drug: Donepezil

Donepezil: 5 mg

Treatment:

Drug: Donepezil

Galantamine: 4 mg

Treatment:

Drug: Galantamine

Galantamine: 8 mg

Treatment:

Drug: Galantamine

Placebo

Treatment:

Other: Placebo